Tenax Therapeutics (TENX) Research & Development (2010 - 2026)

Tenax Therapeutics has disclosed Research & Development across 16 years of filings, most recently posting $12.8 million for Q2 2026.

• In Q2 2026, Research & Development rose 109.93% year-over-year to $12.8 million; the TTM figure through Jun 2026 stood at $45.3 million (up 131.97% YoY), while the FY2025 annual figure was $32.7 million, up 157.08% from the prior year.
• Research & Development came in at $12.8 million for Q2 2026 at Tenax Therapeutics, up from $11.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $12.8 million in Q2 2026 to a low of $197903.0 in Q2 2023.
• Average Research & Development over 5 years is $4.4 million, with a median of $2.5 million recorded in 2024.
• Year-over-year, Research & Development plunged 94.74% in 2022 and surged 1075.83% in 2024.
• Over 5 years, Research & Development stood at $1.1 million in 2022, then jumped by 49.76% to $1.7 million in 2023, then soared by 170.31% to $4.6 million in 2024, then jumped by 129.43% to $10.5 million in 2025, then gained by 21.92% to $12.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $12.8 million in Q2 2026, $11.5 million in Q1 2026, and $10.5 million in Q4 2025.